Russian Heart Failure Journal 2013year Taurin in therapy of chronic heart failure and type 2 diabetes mellitus: Effect on microcirculation and elastic properties of conduit blood vessels

To access this material please log in or register

Register Authorize

Taurin in therapy of chronic heart failure and type 2 diabetes mellitus: Effect on microcirculation and elastic properties of conduit blood vessels

Statsenko M. E., Vinnikova A. A., Ronskaya A. M., Shilina N. N.

Keywords: Dibicor, microcirculation, type 2 diabetes mellitus, taurin, CHF, blood vessel elasticity

DOI: 10.18087/rhfj.2013.6.1886

Background. High incidence of CHF and type 2 DM, poor prognosis and low quality of life determine the need for optimum therapy. The most important part of therapy in this patient category is correction of metabolic disorders underlying development and progression of CHF and DM, i.e., lipid and glucose toxicity and insulin resistance. Aim. Studying effects of taurin as a part of combination therapy for CHF and type 2 DM in respect of the taurin effect of elasticity of large blood vessels and microcirculation. Materials and methods. The study included 60 patients in the early postinfarction period (weeks 3–4 of MI onset) with FC II–III CHF and concurrent type 2 DM. The patients were divided into two groups with 30 patients in each: group 1 (control group), patients receiving a basis therapy for HF in the postinfarction period and oral antihyperglycemic drugs, and group 2, (experimental group), patients receiving taurin (Dibicor, PIK-FARMA, Russia) 500 mg 2 times daily in addition to the basis therapy. Evaluation of patients included the 6min walk test and measurements of blood NT-proBNP, glucose, insulin, glycated hemoglobin, total cholesterol, LDL, HDL, TG, and GFR, echoCG and microcirculation parameters. Results. The 16week taurin treatment provided improvement of microcirculation parameters, which was most pronounced in patients with the spastic type of microcirculation. The taurin therapy resulted in redistribution of microcirculation types towards normocirculation. Taurin exerted a beneficial effect on elastic properties of conduit blood vessels, improved the endothelial function, lipid and carbohydrate metabolism, and reduced insulin resistance. Conclusion. It is advisable to include taurin into the basis therapy for CHF and type 2 DM in the early postinfarction period.
  1. Стаценко М. Е., Фабрицкая С. В., Туркина С. В. и др. Особен­ности поражения органов–мишеней, состояния углеводного и липидного обменов, качества жизни у пациентов с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Журнал Сердечная Недостаточность. 2010;11 (4):206–212.
  2. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распро­страненность хронической сердечной недостаточности в Евро­пей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная недостаточность. 2011;12 (5):254–262.
  3. Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol. 2012;771:35–41.
  4. Tartière-Kesri L, Tartière JM, Logeart D et al. Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2012;59 (5):455–461.
  5. Marti CN, Gheorghiade M, Kalogeropoulos AP et al. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60 (16):1455–1469.
  6. Lilly SM, Qasim AN, Mulvey CK et al. Non-compressible arterial disease and the risk of coronary calcification in type-2 diabetes. Atherosclerosis. 2013;230 (1):17–22.
  7. Chen LZ, Wang B, Zhang H, Yang JM. Analyses of carotid intima-media thickness and quantitative arterial stiffness in type 2 diabetes mellitus patients with follow-ups. Zhonghua Yi Xue Za Zhi. 2013;93 (12):927–929.
  8. Покровская Е. М., Волов Н. А., Васильева И. С. Новые возможности лечения пациентов с сердечной недостаточностью вследствие постинфарктного кардиосклероза. Медицинский совет. 2012;12:18–23.
  9. Schaffer SW, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol. 2009;87 (2):91–99.
  10. Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek. 2011;68 (6):334–338.
  11. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000;18 (4):305–318.
  12. Satoh H, Kang J. Modulation by taurine of human arterial stiffness and wave reflection. Adv Exp Med Biol. 2009;643:47–55.
  13. Abebe W, Mozaffari MS. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis. 2011;1 (3):293–311.
  14. El Idrissi A, Okeke E, Yan X et al. Taurine regulation of blood pressure and vasoactivity. Adv Exp Med Biol. 2013;775:407–425.
  15. Шестакова М. В., Чугунова Л. А., Шамхалова М. Ш. Опыт применения Дибикора при сахарном диабете 2 типа. Сахарный диабет 2007;1:2–3.
  16. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  17. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2011;5:1–72.
  18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130 (6):461–470.
  19. Lang RM, Bierig M, Devereux RB et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7 (2):79–108.
  20. Крупаткин А. И., Сидоров В. В. Лазерная допплеровская флоуметрия микроциркуляции крови. – М.: Медицина, 2005. – 256 с.
  21. Маколкин В. И. Микроциркуляция в кардиологии. –М.: «Визарт», 2004. – 135с.
  22. Peterson LH, Jensen RE, Parnell J. Mechanical properties of arteries in vivo. Circulation Res. 1960;8:622–639.
  23. Звенигородская Л. А., Овсянникова О. Н., Носкова К. К. и др. Таурин в лечении неалкогольной жировой болезни печени. Экспе­ри­ментальная и клиническая гастроэнтерология. 2010;7:43–50.
Statsenko M. E., Vinnikova A. A., Ronskaya A. M. et al. Taurin in therapy of chronic heart failure and type 2 diabetes mellitus: Effect on microcirculation and elastic properties of conduit blood vessels. Russian Heart Failure Journal. 2013;14 (6):362-368

To access this material please log in or register

Register Authorize
Ru En